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Abstract The aim of this work was to study the e¡ect of a
sustained activation of AMP-activated protein kinase (AMPK)
on liver cell survival. AMPK activation was achieved by incu-
bating FTO2B cells with AICA-riboside, which is transformed
into ZMP, an AMP analogue, or by adenoviral transfection of
hepatocytes with a constitutively active form of AMPK. Pro-
longed AMPK activation triggered apoptosis and activated
c-Jun N-terminal kinase (JNK) and caspase-3. Experiments
with iodotubercidin, dicoumarol and z-VAD-fmk, which inhib-
ited AMPK, JNK and caspase activation, respectively, sup-
ported the notion that prolonged AMPK activation in liver cells
induces apoptosis through an activation pathway that involves
JNK and caspase-3. 1 2002 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
The energy status of the cell, and especially ATP concen-
tration, plays a crucial role in cell survival and prolonged
ATP depletion leads to cell death. Small changes in ATP do
not necessarily result in cell death but are sensed by cells. A
fall in ATP with a subsequent rise in AMP activate the AMP-
activated protein kinase (AMPK), which is considered as a
‘fuel gauge’ [1^3]. AMPK acts as a metabolic master switch
by inactivating key enzymes of anabolic processes that con-
sume ATP [2,4,5]. It also favors fatty acid oxidation [6] and,
in certain cells, it stimulates glycolysis by increasing glucose
transport and by activating 6-phosphofructo-2 kinase [7],
thereby favoring ATP production. ATP conservation is there-
fore the net result of AMPK activation, which contributes to
liver cell survival in the short term [8]. However, consequences
of prolonged stress and of a sustained AMPK activation on
cell survival have not been investigated. To study the e¡ects of
a sustained AMPK activation, cells were incubated with
5-aminoimidazole-4-carboxamide (AICA) riboside, an adeno-
sine analogue, which activates AMPK after its phosphoryla-
tion to AICA-ribotide (ZMP), an AMP analogue [9]. This
occurs in certain cells, such as hepatocytes or hepatoma cell
lines [10,11]. Incubation of these cells with AICA-riboside also
has the advantage of activating AMPK without a¡ecting the
adenine nucleotide levels [3], thus allowing the e¡ects of pro-
longed AMP activation on cell survival to be studied indepen-
dently of ATP depletion.
2. Materials and methods
2.1. Cell culture and adenoviral infection
FTO2B cells were maintained in Dulbecco’s modi¢ed Eagle’s me-
dium/Ham’s F12 medium (Life Technologies) supplemented with 10%
fetal bovine serum (BioWhittaker Europe), 75 mg/l penicillin sulfate
and 100 mg/l streptomycin. Rat hepatocytes were isolated and cul-
tured as in [12]. Z-Val-Ala-Asp-£uoromethylketone (z-VAD-fmk,
from Bachem), dicoumarol and iodotubercidin (from Sigma) were
added 30 min before AICA-riboside (from Sigma). Primary cultures
of hepatocytes were infected either with a control adenovirus (Ad-
Null), or with an adenovirus containing the constitutively active
form of AMPK (Ad-CA-AMPK) as in [13].
2.2. Detection and quanti¢cation of apoptosis
To demonstrate apoptosis, four methods were used: (1) the percent-
age of cells containing sub-G1 (apoptotic) nuclei were counted by
FACS analysis [14,15]; (2) phosphatidylserine externalization was
measured by labelling the cells with Annexin V-FITC (100 Wg)
(RpD Systems) and propidium iodide (0.1 Wg), and monitored by
FACS analysis (FITC, emission at 527 nm; propidium iodide, emis-
sion at 590 nm); (3) DNA laddering was detected after extraction of
FTO2B cells DNA using the ‘apoptotic DNA ladder kit’ (from Amer-
sham) and electrophoresis in a 2% agarose gel containing ethidium
bromide; and (4) caspase-3 activity was assayed using Ac-DEVD-
AMC (N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin) as
£uorogenic substrate (from Biosource). Cells were lysed in a bu¡er
containing 0.1% (w/v) CHAPS, 10 mM dithiothreitol (DTT), 10 mM
HEPES pH 7.4, 2 mM EDTA, 1 mM phenylmethylsulfonyl £uoride,
10 Wg/ml leupeptin, 10 Wg/ml aprotinin and 20 Wg/ml pepstatin. Cell
lysates (25^50 Wg of protein) were incubated with 50 WM Ac-DEVD-
AMC for 3 h at 20‡C and AMC £uorescence was measured (excita-
tion at 360 nm, emission at 460 nm). The rate of AMC produced was
linear as a function of time and of the amount of extracts. Caspase-3
activity is expressed as pmol of AMC formed/min/mg of protein.
2.3. Protein kinase assays and other methods
AMPK activity was measured as in [7]. The activity of c-myc-tagged
CA-AMPK protein was measured as in [13]. c-Jun N-terminal kinase
(JNK) activity was measured in cell lysates (300 Wg of protein) after
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immunoprecipitation with 300 ng of anti-JNK1 antibody (kindly pro-
vided by J. Vandenheede, KUL, Leuven, Belgium) bound to protein
A-Sepharose (from Pharmacia Biotech). The immunoprecipitates were
¢rst washed in PBS containing 1 mM Na3VO4 and 1% (w/v) NP-40,
and then in kinase reaction bu¡er (20 mM HEPES, pH 7.5, 2 mM
EGTA, 25 mM MgCl2, 1 mM DTT, 0.1% (w/v) Triton X-100, 1 mM
Na3VO4), and incubated with 1 Wg GST-c-jun-1^79 (Alexis) in the
presence of 20 WM Mg[Q-32P]ATP (27 500 cpm/pmol, Amersham).
Phosphorylation of GST-c-jun-1^79 was quanti¢ed by phosphorimag-
ing after 10% SDS^PAGE. One unit of protein kinase activity corre-
sponds to 1 nmol of phosphate incorporated/min. Protein was esti-
mated by Coomassie blue staining (Bio-Rad). Student’s two-way t-test
for paired data was used to assess the statistical signi¢cance of di¡er-
ences.
3. Results
3.1. AICA-riboside induces apoptosis in FTO2B cells
Incubation of FTO2B cells with 2 mM AICA-riboside led
to AMPK activation, which was detectable after 15 min, max-
imal after 1 h and remained above the control values for at
least 24 h (Fig. 1A). At 24 h, labelling the cells with propi-
dium iodide indicated that the number of dead cells increased
(data not shown). The occurrence of apoptosis was demon-
strated as follows. First, the percentage of nuclei containing
subdiploid (sub-G1) amounts of DNA in FTO2B cells incu-
bated for 36 h with di¡erent concentrations of AICA-riboside
increased from 13S1.1 (controls) to 68S 1.5 (2 mM AICA-
riboside, n=5). Second, DNA laddering was observed after
24 h with 2 mM AICA-riboside (Fig. 2A). Third, a dose-de-
pendent increase in the externalization of phosphatidylserine
was detected by annexin V labelling (Fig. 3).
DNA fragmentation and phosphatidylserine externalization
were blocked by z-VAD-fmk, the general caspase inhibitor
(Figs. 2B and 3). Accordingly, exposure to 2 mM AICA-ribo-
side signi¢cantly increased the activity of caspase-3, the major
e¡ector caspase, after 6^8 h of treatment and onwards (Fig.
1B); the e¡ect was apparent at 1 mM AICA-riboside and
maximal at 5 mM AICA-riboside (data not shown). Cas-
pase-3 activation was prevented if AICA-riboside was re-
moved from the culture medium within the ¢rst 10 h of in-
cubation. After this critical time point, apoptosis was
inescapable (data not shown). Therefore, a sustained AICA-
riboside treatment was required to induce apoptosis. The de-
lay between AMPK activation and the onset of caspase-3
activation suggests that an intermediate signal mediates apo-
ptosis induction.
3.2. AMPK activation leads to JNK activation and is required
for the induction of apoptosis
Activation of stress-activated protein kinases, such as JNK
Fig. 1. Activation of AMPK (A) and caspase-3 (B) in FTO2B cells
incubated with AICA-riboside. FTO2B cells were cultured for the
indicated periods of time without (open squares) or with 2 mM
AICA-riboside (¢lled squares). The values are the meansSS.E.M.
for ¢ve (A) or six (B) experiments. *Signi¢cantly di¡erent from the
control values (P6 0.05).
Fig. 2. DNA laddering in FTO2B cells incubated with AICA-ribo-
side. A: FTO2B cells were cultured in the absence (3) or in the
presence (+) of 2 mM AICA-riboside (AICAr) for the indicated pe-
riods of time. B: FTO2B cells were cultured in the absence (3) or
in the presence (+) of 5 mM AICA-riboside (AICAr) for 48 h with-
out (3) or with (+) 100 WM z-VAD-fmk (z-VAD).
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or p38 mitogen-activated protein kinase, induces apoptosis in
certain cells [16,17]. No activation of p38 could be detected in
FTO2B cells treated with AICA-riboside and SB203580, the
inhibitor of p38 activation, did not prevent apoptosis (data
not shown). By contrast, JNK activation was detectable with-
in 1 h, was maximal at 2 h and persisted for at least 10 h after
AICA-riboside exposure (Fig. 4A), indicating that JNK acti-
vation followed AMPK activation and preceded caspase-3
activation. Moreover, z-VAD-fmk did not prevent JNK acti-
vation by AICA-riboside (data not shown), suggesting that
caspases did not mediate JNK activation.
Incubation of FTO2B cells with 10 WM iodotubercidin, an
inhibitor of adenosine kinase which blocks ZMP formation
from AICA-riboside [18], completely blocked the activation
of AMPK, JNK and caspase-3 induced by AICA-riboside
(data not shown). On the other hand, dicoumarol, an inhib-
itor of JNK activation [19], prevented the activation of both
JNK and caspase-3 (Fig. 4B) but not AMPK (data not
shown). These results suggest that AICA-riboside induces ap-
optosis through an activation cascade involving AMPK, JNK
and subsequently caspase-3.
Finally, the pro-apoptotic e¡ect of AICA-riboside was con-
¢rmed in primary rat hepatocytes, which indeed displayed an
increase in the percentage of apoptotic nuclei as well as an
activation of JNK and caspase-3 (data not shown). To dem-
onstrate that AMPK activation by itself su⁄ces to induce
apoptosis, we infected hepatocytes with an adenovirus encod-
ing a truncated K1-AMPK catalytic subunit (c-myc tagged,
and with a Thr-172-Asp mutation in the activation loop).
The mutated subunit acts as a constitutively active form of
Fig. 3. FACS analysis of FTO2B cells labelled with annexin V and propidium iodide after incubation with AICA-riboside. A: FTO2B cells
were cultured for 24 h in the absence (control) or in the presence of 2.5 mM of AICA-riboside. Cells were stained with annexin V and propidi-
um iodide and analyzed by £ow cytometry as described in Section 2. The y-axis represents the propidium iodide channel; the x-axis represents
the annexin channel. Percentage of total cells in quadrants corresponds to living cells (propidium iodide- and annexin V-negative cells, left), ne-
crotic and late apoptotic cells (propidium iodide- and annexin V-positive cells, upper right), and early apoptotic cells (annexin V-positive cells,
lower right). B: FTO2B cells were cultured in the presence of the indicated concentrations of AICA-riboside (AICAr) for 24 h in the absence
(3) or in the presence (+) of 100 WM of z-VAD-fmk and analyzed as in Fig. 3A. Black columns: annexin V-positive cells, white columns: pro-
pidium iodide-positive cells.
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AMPK when overexpressed in hepatocytes [13]. Expression of
the constitutively active AMPK resulted in the activation of
both JNK and caspase-3 (Fig. 5), thus demonstrating that
AMPK activation is su⁄cient to induce apoptosis.
4. Discussion
Here we demonstrate that AMPK activation can lead to the
induction of apoptosis in liver cells. This is the ¢rst demon-
stration of a pro-apoptotic e¡ect of AMPK. Our results also
suggest that apoptosis induction by AMPK is mediated by
JNK. AMPK activation had to be sustained (s 10 h) to trig-
ger apoptosis. This time course is in agreement with the pre-
vious observations that a sustained rather than a transient
JNK activation is associated with apoptosis [20]. The delay
between AMPK activation and the onset of apoptosis may
correspond to the time required to accumulate pro-apoptotic
proteins in excess of anti-apoptotic proteins. Proteins such as
p53, Bax and Fas ligand have indeed been shown to be upreg-
ulated or activated by JNK [21^23].
Our results contrast with earlier reports which showed that
AICA-riboside inhibits apoptosis induced by dexamethasone,
fatty acids or high glucose concentrations in thymocytes, as-
trocytes and human umbilical vein endothelial cells, respec-
tively [24^26]. In these experiments, AICA-riboside was antag-
Fig. 4. E¡ects of AICA-riboside and dicoumarol on JNK and cas-
pase-3 activities in FTO2B cells. A: FTO2B cells were cultured for
the indicated periods of time without (open squares) or with 2 mM
AICA-riboside (¢lled squares). B: E¡ects of pre-treatment with 100
WM of dicoumarol (Dicum) on JNK and caspase-3 activation in
FTO2B cells exposed to 5 mM AICA-riboside for 1.5 and 15 h, re-
spectively. The values are the meansSS.E.M. for ¢ve experiments.
*Signi¢cantly di¡erent from the control values; **signi¢cantly dif-
ferent from the AICA-riboside-treated cells values (P6 0.05).
Fig. 5. Infection of hepatocytes with adenovirus containing the con-
stitutively active form of AMPK induces JNK and caspase-3 activa-
tion. Primary rat hepatocytes were infected with control adenovirus
(Ad-Null) or with adenovirus expressing the constitutively active
form of AMPK (Ad-CA-AMPK) at 30 pfu/cell, or remained unin-
fected (control) for 30 h. Speci¢c activities of JNK and caspase-3
were determined as described in Section 2. The values are the means
SS.E.M. for six independent experiments. *Signi¢cantly di¡erent
from the control values; **signi¢cantly di¡erent from the Ad-Null-
infected cells values (P6 0.05).
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onizing the pro-apoptotic e¡ects of various substances. How-
ever, we have no simple explanation for the di¡erence between
these results and our data, but it is likely that the e¡ect of
AMPK activation on cell survival may depend on the cell
type, the environmental conditions and on the duration of
kinase activation.
Finally, we speculate that prolonged AMPK activation fa-
vors apoptosis over necrosis, because of the ATP-preserving
e¡ects of its activation. However, if ATP depletion is drastic,
as is the case during anoxia, AMPK activation is transient [7]
and necrosis rather than apoptosis is expected. Therefore it
seems that the duration of AMPK activation, as well as the
extent and rapidity of ATP depletion, might be crucial for
determining the type of cell death.
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